Bacil Pharma will raise up to ₹50 crore through a Rights Issue. The company also approved a capital increase to ₹65 crore. Two independent directors resigned citing time constraints.
Bacil Pharma Eyes ₹50 Crore Capital Infusion via Rights Issue
Bacil Pharma Limited plans to raise up to ₹50 crore through a Rights Issue of equity shares. The company's Board of Directors has also approved an increase in its authorized share capital by ₹45 crore, taking the total post-increase authorized capital to ₹65 crore. This move is aimed at strengthening the company's financial base. The proposal requires shareholder approval at an upcoming general meeting.
What just happened
Bacil Pharma announced plans for a ₹50 crore rights issue and a ₹45 crore increase in authorized capital to ₹65 crore. Two independent directors resigned.
Why this matters
The capital raise can fund growth initiatives, while the director resignations may raise governance questions for investors.
The backstory
Bacil Pharma Limited is a pharmaceutical company seeking to enhance its capital structure through a rights issue. The company has established a dedicated Rights Issue Committee to manage this process.
What changes now
The company will form a Rights Issue Committee and appoint intermediaries like a registrar and banker. The capital hike and rights issue are subject to shareholder and regulatory approvals.
Risks to watch
Investors should monitor the terms of the rights issue and any further board appointments or changes. The reasons for director resignations, though cited as time constraints, warrant attention.
Peer comparison
(No direct peer comparison information is available in the filing.)
Context metrics (time-bound)
- Proposed Rights Issue Amount: ₹50 crore
- Authorized Capital Increase: ₹45 crore
- Post-Increase Authorized Capital: ₹65 crore
- Independent Director Resignations: Effective July 9, 2026
What to track next
Investors should watch for the formal announcement of the rights issue dates, pricing, and ratio, as well as any new board appointments.